Informational only — Not medical advice. Always consult a licensed healthcare provider.

Community data Updated 2 months ago
10 mg/10 ml
10 mg vial
৳15,500.00 per pack

Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.

All price changes →
I

Idarubicin PhaRes

Rx

10 mg/10 ml • IV Infusion

Therapeutic class: Cytotoxic Chemotherapy
🌐 বাংলায় দেখুন
From ৳15,500.00 10 mg vial
Available as: 10 mg/10 ml · 10 mg vial

Indications & Uses

Idarubicin PhaRes is indicated for:

Pharmacology

Idarubicin hydrochloride is an analog of daunorubicin that works by intercalating into DNA. It inhibits the synthesis of nucleic acids and interacts with the enzyme topoisomerase II. The anthracycline structure of idarubicin has no methoxy group at position 4, and this makes the compound highly lipophilic. As a result, cells take it up faster than they take up other anthracyclines.

Dosage Reference

Reference Information Only

Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.

Adults:

For induction therapy in adults with AML, the recommended schedule is idarubicin hydrochloride 12 mg/m2 daily for 3 days, given by slow intravenous injection over 10 to 15 min, together with cytarabine. The cytarabine can be given as 100 mg/m2 daily by continuous infusion for 7 days. Or it can be given as a 25 mg/m2 intravenous bolus, followed by 200 mg/m2 daily for 5 days by continuous infusion.

If there is unequivocal evidence of leukemia after the first induction course, a second course may be given. Patients who develop severe mucositis should have the second course delayed until they have recovered from it, and a dose reduction of 25% is recommended. In patients with hepatic and/or renal impairment, a dose reduction of idarubicin should be considered. Idarubicin should not be given if the bilirubin level is above 5 mg%.

The benefit of consolidation in prolonging the duration of remissions and survival is not proven. There is no consensus on which optional regimens to use for consolidation.

Pediatric Use: Safety and effectiveness in children have not been established.

Side Effects

Side-effect information is not available for this brand yet.

Cautions & Contraindications

Warnings & Precautions

Idarubicin Hydrochloride PhaRes should be given only under the supervision of a physician who has experience in leukemia chemotherapy. Idarubicin Hydrochloride is a potent bone marrow suppressant. It should not be given to patients whose bone marrow is already suppressed by earlier drug therapy or radiotherapy, unless the benefit justifies the risk. Every patient given a therapeutic dose for induction, consolidation or maintenance will develop severe myelosuppression. Careful hematologic monitoring is required. Deaths due to infection and/or bleeding have been reported during the period of severe myelosuppression. So the facility must have laboratory and supportive resources adequate to monitor how well the patient tolerates the drug, and to protect and maintain a patient compromised by its toxicity. A severe hemorrhagic condition and/or a severe infection must be treatable rapidly and completely. Pre-existing heart disease, previous therapy with anthracyclines at high cumulative doses, and other potentially cardiotoxic agents are co-factors that raise the risk of cardiac toxicity from idarubicin. In such patients, the benefit to risk ratio should be weighed before treatment with Idarubicin Hydrochloride is started. Myocardial toxicity may follow therapy, and it can show up as potentially fatal congestive heart failure, acute life-threatening arrhythmias or other cardiomyopathies. Appropriate therapeutic measures for managing congestive heart failure and/or arrhythmias are indicated.

Pregnancy & Breastfeeding

Idarubicin is Pregnancy Category D. In rats, it was embryotoxic and teratogenic at 1.2 mg/m2/day, which is one tenth of the human dose and did not poison the mother animals. In rabbits it was embryotoxic but not teratogenic, even at 2.4 mg/m2/day (two tenths of the human dose), and that dose was toxic to the mothers. No conclusive information shows that idarubicin harms human fertility or causes teratogenesis. There has been one report of a fetal death after the mother was exposed to idarubicin in the second trimester. No adequate and well-controlled studies have been done in pregnant women.

If Idarubicin is used during pregnancy, or if the patient becomes pregnant during treatment, she should be told about the possible hazard to the fetus. Women who could become pregnant should be advised to avoid pregnancy.

Nursing mothers: It is not known whether idarubicin passes into human milk. Many drugs do pass into milk, and idarubicin could cause serious adverse reactions in a nursing infant, so mothers should stop nursing before they take this medicine.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Storage

Keep Idarubicin Hydrochloride at controlled room temperature, between 15° and 30°C, and away from light.

Common questions about Idarubicin PhaRes 10 mg/10 ml

What is Idarubicin PhaRes 10 mg/10 ml IV Infusion?

Idarubicin PhaRes 10 mg/10 ml IV Infusion is a medicine that contains Idarubicin Hydrochloride. It is made by ZAS Corporation. It belongs to the Cytotoxic Chemotherapy group of medicines.

What is Idarubicin PhaRes used for?

Idarubicin PhaRes is used for: Cancer.

Can I take Idarubicin PhaRes during pregnancy or while breastfeeding?

Idarubicin is Pregnancy Category D. In rats, it was embryotoxic and teratogenic at 1.2 mg/m2/day, which is one tenth of the human dose and did not poison the mother animals. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

How should I store Idarubicin PhaRes?

Keep Idarubicin Hydrochloride at controlled room temperature, between 15° and 30°C, and away from light.

Do I need a prescription for Idarubicin PhaRes?

Idarubicin PhaRes is a prescription (Rx) medicine. Take it as your doctor advises.

Last updated: 18 Aug 2026